## Analysis of Fat-soluble Vitamins Using the Nexera ${ }^{\text {TM }}$ UC Supercritical Fluid Chromatograph

Vitamins are essential micronutrients to maintain the normal functioning of organisms, but they must be ingested from food because they are not synthesized sufficiently in the body. Deficiencies of vitamins in the body cause symptoms such as disease and growth disorders. Vitamin A is associated with night blindness and skin abnormalities, vitamin $D$ with rickets and osteomalacia, vitamin E with anemia and blood circulation disorders, and vitamin K with hemorrhaging, osteoporosis, etc. Therefore, it is very important to accurately analyze the fat-soluble vitamins in foods and supplements. The fat-soluble vitamins are broadly classified into vitamin A, vitamin D, vitamin E, and vitamin K according to their chemical structure and physiological effects. Due to the large number of isomers, good separation is required for fat-soluble vitamin analysis.
Here we introduce an example of a simultaneous analysis of fat-soluble vitamins using a supercritical fluid chromatograph (SFC) and triple quadrupole mass spectrometer for detection.

H. Terada, T. Hattor

## Target Components and Analysis Conditions

Table 1 lists fat-soluble vitamins and related substances targeted in this study, and the MRM conditions for MS. In addition, the analysis conditions for SFC are summarized in Table 2. Fig. 1 shows a chromatogram obtained from the analysis of standard samples in which the concentration of each fat-soluble vitamin is $1 \mu \mathrm{~mol} / \mathrm{L}$.

Table 1 Target Components and MRM Conditions

| No. | Compounds |  | Transition | Classification |
| :---: | :---: | :---: | :---: | :---: |
| 1 | Retinol | ESI (+) | 269.30>93.00 | Vitamin A |
| 2 | Retinal | ESI (+) | $285.20>161.00$ |  |
| 3 | Retinoate | ESI (+) | $301.20>122.90$ |  |
| 4 | beta-Carotene | ESI (+) | 536.60>444.00 | Precursor of Vitamin A |
| 5 | Ergocalciferol (Vitamin D2) | ESI (+) | $397.50>107.10$ | Vitamin D |
| 6 | Cholecalciferol (Vitamin D3) | ESI (+) | $384.80>367.10$ |  |
| 7 | Calcidiol (25(OH)D3) | ESI (+) | $401.40>383.00$ |  |
| 8 | Calcitriol (1,25-(OH)2D3) | ESI (+) | $399.30>398.80$ |  |
| 9 | 25-Hydroxyergocalciferol (25(OH) D2) | ESI (+) | $412.80>395.00$ |  |
| 10 | 1-alpha-25Dihydroxyergocalciferol (1,25-(OH)2D2) | ESI (+) | $411.40>134.80$ |  |
| 11 | alpha-Tocopherol | ESI (+) | $430.80>164.80$ | Vitamin E |
| 12 | beta-Tocopherol | ESI (+) | $416.80>151.00$ |  |
| 13 | gamma-Tocopherol | ESI (+) | $416.80>150.80$ |  |
| 14 | delta-Tocopherol | ESI (+) | $402.80>136.80$ |  |
| 15 | alpha-Tocotrienol | ESI (+) | $424.80>164.80$ |  |
| 16 | gamma-Tocotrienol | ESI (+) | $410.80>150.80$ |  |
| 17 | delta-Tocotrienol | ESI (+) | $396.80>136.80$ |  |
| 18 | alpha-Tocopherolquinone | ESI (+) | $429.20>165.15$ |  |
| 19 | Phylloquinone (Vitamin K1) | ESI (+) | $451.40>186.80$ | Vitamin K |
| 20 | Menaquinone (Vitamin K2) | ESI (+) | $445.30>186.80$ |  |

## Table 2 Analysis Conditions

Column
Mobile phase
Gradient
Flow rate
Column temp.
BPR pressure
Detector
Makeup
Makeup flow rate
Injection vol

Shim-pack ${ }^{\text {TM }}$ UC-RP ( $150 \mathrm{~mm} \mathrm{L}. \times 2.1 \mathrm{~mm}$ I.D., $3 \mu \mathrm{~m}$ ) $\mathrm{A} ; \mathrm{CO}_{2}$
B; 0.1 \% (w/v) Ammonium formate in methanol
: B.conc. $5 \%(0 \mathrm{~min})-10 \%(6 \mathrm{~min})-30 \%(10 \mathrm{~min})-$
$50 \%(10.1-15 \mathrm{~min})-5 \%(15.1-18 \mathrm{~min})$
$0.8 \mathrm{~mL} / \mathrm{min}$
$40^{\circ} \mathrm{C}$
10 MPa
: LCMS ${ }^{\text {TM }}$-8050 (ESI, MRM mode)
$0.1 \%(\mathrm{w} / \mathrm{v})$ Ammonium formate in methanol $0.05 \mathrm{~mL} / \mathrm{min}$ : $1 \mu \mathrm{~L}$


1. Retinol
2. Retinal
3. Retinoate
4. beta-Carotene
5. Ergocalciferol
6. Cholecalciferol
7. Calcidiol
8. Calcitriol
9. 25-Hydroxyergocalciferol

10 1-alpha-25-Dihydroxyergocalciferol
11 alpha-tocopherol
12 beta-tocopherol
13 gamma-tocopherol
14 delta-tocopherol
15 alpha-tocotrienol
16 gamma-tocotrienol
17 delta-tocotrienol
18 a-tocopherolquinone
19 Phylloquinone
20 Menaquinone

Fig. 1 Chromatogram for Standard Solutions ( $1 \mu \mathrm{~mol} / \mathrm{L}$ )

## Calibration Range and Sensitivity

Table 3 gives the information on the calibration curves and limits of detection obtained by analyzing standard samples in which the concentration of each fat-soluble vitamin was 0.01 to $10 \mu \mathrm{~mol} / \mathrm{L}$.

Table 3 Linearity and Limits of Detection

| Compounds | Concentration <br> $(\mu \mathrm{mol} / \mathrm{L})$ | $\mathrm{R}^{2}$ | LOD <br> $(\mathrm{nmol} / \mathrm{L})$ |
| :--- | :---: | :---: | :---: |
| Retinol | $0.01-10$ | 0.9997 | 20 |
| Retinal | $0.01-10$ | 0.9993 | 9.1 |
| Retinoate | $0.01-10$ | 0.9964 | 14 |
| beta-Carotene | $0.01-10$ | 0.9986 | 0.40 |
| Ergocalciferol | $0.05-10$ | 0.9993 | 47 |
| Cholecalciferol | $0.01-10$ | 0.9953 | 15 |
| Calcidiol | $0.01-10$ | 1.0000 | 24 |
| Calcitriol | $0.05-10$ | 0.9988 | 25 |
| 25-Hydroxyergocalciferol | $0.01-10$ | 0.9988 | 17 |
| 1-alpha-25-Dihydroxyergocalciferol | $0.01-10$ | 0.9995 | 0.80 |
| alpha-Tocopherol | $0.01-10$ | 0.995 | 2.2 |
| beta-Tocopherol | $0.01-10$ | 0.9973 | 16 |
| gamma-Tocopherol | $0.01-10$ | 0.9992 | 32 |
| delta-Tocopherol | $0.02-10$ | 0.9988 | 12 |
| alpha-Tocotrienol | $0.01-5$ | 0.9988 | 1.1 |
| gamma-Tocotrienol | $0.02-10$ | 0.9999 | 8.3 |
| delta-Tocotrienol | $0.01-10$ | 0.9983 | 4.3 |
| alpha-Tocopherolquinone | $0.01-10$ | 0.9971 | 0.90 |
| Phylloquinone | $0.01-10$ | 0.9991 | 2.3 |
| Menaquinone | $0.01-10$ | 0.9983 | 4.8 |

* beta-Carotene only: secondary approximation


## Repeatability

Table 4 gives the repeatability of the retention time and peak area of each fat-soluble vitamin, which was obtained by analyzing the $1 \mu \mathrm{~mol} / \mathrm{L}$ standard samples six times.

Table 4 Repeatability

| Compounds | Retention Time |  | Peak Area |  |
| :--- | :---: | :---: | :---: | :---: |
|  | $(\mathrm{min})$ | RSD <br> $(\%)$ | Average | RSD <br> $(\%)$ |
|  | 3.485 | 0.112 | 512700 | 3.72 |
| Retinal | 2.149 | 0.365 | 730359 | 3.99 |
| Retinoate | 4.270 | 0.307 | 374720 | 2.71 |
| beta-Carotene | 10.882 | 0.114 | 15022154 | 2.74 |
| Ergocalciferol | 5.376 | 0.357 | 572484 | 3.24 |
| Cholecalciferol | 5.459 | 0.239 | 2113522 | 3.22 |
| Calcidiol | 6.237 | 0.0880 | 1898273 | 3.84 |
| Calcitriol | 7.324 | 0.202 | 378473 | 3.74 |
| 25-Hydroxyergocalciferol | 5.902 | 0.219 | 1076576 | 3.36 |
| 1-alpha-25-Dihydroxyergocalciferol | 6.883 | 0.197 | 2088882 | 4.83 |
| alpha-Tocopherol | 5.979 | 0.240 | 1137057 | 3.92 |
| beta-Tocopherol | 6.174 | 0.0820 | 283144 | 4.32 |
| gamma-Tocopherol | 6.308 | 0.138 | 411577 | 5.94 |
| delta-Tocopherol | 5.646 | 0.247 | 205092 | 2.24 |
| alpha-Tocotrienol | 6.531 | 0.394 | 343701 | 3.18 |
| gamma-Tocotrienol | 6.882 | 0.264 | 298561 | 3.62 |
| delta-Tocotrienol | 6.182 | 0.467 | 192646 | 2.61 |
| alpha-Tocopherolquinone | 2.583 | 0.371 | 7867923 | 3.94 |
| Phylloquinone | 3.485 | 0.300 | 2055829 | 3.76 |
| Menaquinone | 3.678 | 0.336 | 1637582 | 2.17 |

## Analysis of Fat-soluble Vitamins in Supplements

Fig. 2 shows the chromatogram obtained from the analysis of the supplement extract containing vitamin $D$ and vitamin $K$. The supplement was crushed, subjected to extraction with nhexane, centrifugation and then filtration with a membrane filter. Cholecalciferol and menaquinone were detected in the same sample. Table 5 shows the results of spiking the extract with the equivalent of $1 \mu \mathrm{~mol} / \mathrm{L}$ of cholecalciferol and menaquinone and checking the recovery rate. A good recovery rate was obtained with both components.


Table 5 Spike-and-Recovery Test Results

| Component |  | Cholecalciferol | Menaquinone |
| :---: | :---: | :---: | :---: |
| Concentration <br> $(\mu \mathrm{mol} / \mathrm{L})$ | No spike | 0.05 | 0.116 |
|  | $1 \mu \mathrm{~mol} / \mathrm{L}$ equivalent added | 1.109 | 1.062 |
| Recovery rate (\%) |  |  | 106 |
| 94.6 |  |  |  |

Nexera, Shim-pack, and LCMS are trademarks of Shimadzu Corporation in Japan and/or other countries.

Shimadzu Corporation
www.shimadzu.com/an/

For Research Use Only. Not for use in diagnostic procedure.
This publication may contain references to products that are not available in your country. Please contact us to check the availability of these products in your country.

The content of this publication shall not be reproduced, altered or sold for any commercial purpose without the written approval of Shimadzu. Shimadzu disclaims any proprietary interest in trademarks and trade names used in this publication other than its own.
See http://www.shimadzu.com/about/trademarks/index.html for details.
The information contained herein is provided to you "as is" without warranty of any kind including without limitation warranties as to its accuracy or completeness. Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the use of this publication. This publication is based upon the information available to Shimadzu on or before the date of publication, and subject to change without notice.

